Medicare to collect drug price rebates starting in 2025
The CMS has laid out how it plans to implement a key provision of the Inflation Reduction Act requiring drugmakers to pay rebates on price hikes in Medicare that are greater than inflation.
GE HealthCare agrees to buy AI imaging firm Caption Health in second acquisition
GE HealthCare plans to pair its ultrasound machines with Caption’s applications for early disease detection.
HHS readies for PHE wind down, end of pandemic flexibilities
A variety of pandemic-era policies will expire May 11, including flexibilities allowing providers to prescribe controlled substances via telehealth without an in-person visit and rules requiring payers to cover COVID-19 testing.
Tipping point is in sight: Value-based care is driving meaningful financial results
Strata’s Liz Kirk shares her reflections on value-based care from the 41st annual JPMorgan healthcare conference held in San Francisco.
Trade group pushes back on FDA’s clinical decision support guidance
The Clinical Decision Support Coalition is asking the agency to rescind its guidance and propose new rules that change how software tools are regulated as medical devices.
Following decline, telehealth visits notched up 1.9% in November
Mental health conditions continued to dominate telehealth diagnoses last year as the federal government worked to protect telehealth provisions following the looming end to the COVID-19 public health emergency.
Tenet’s net income tumbled in 2022, but labor expenses show signs of easing
The major for-profit hospital operator posted full year net income down about 55% from 2021, and fourth quarter net income down about 60% from the prior year period, according to its earnings report out Thursday.
Molina expects contract wins to offset Medicaid losses
The forecast comes as its competitor, Centene, expects to lose as many as 2.2 million Medicaid members when pandemic protections end and states to resume eligibility checks.
Centene reaches $215M settlement with California
This latest settlement is the largest the payer has announced so far regarding state overcharging allegations.
Cigna restricts coverage of new ALS drug, deepening fears about access
The health insurer’s national formulary considers Amylyx Pharmaceuticals’ Relyvrio to be “experimental, investigational or unproven for any use,” and now does not recommend covering it.